Boston Family Office LLC Buys 17,864 Shares of Boston Scientific Corporation $BSX

Boston Family Office LLC increased its holdings in Boston Scientific Corporation (NYSE:BSX) by 151.9% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 29,624 shares of the medical equipment provider’s stock after buying an additional 17,864 shares during the quarter. Boston Family Office LLC’s holdings in Boston Scientific were worth $2,825,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Murphy & Mullick Capital Management Corp raised its holdings in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares in the last quarter. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the 2nd quarter worth $26,000. Swiss RE Ltd. purchased a new stake in Boston Scientific in the fourth quarter valued at about $26,000. Colonial Trust Co SC raised its stake in Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 231 shares during the last quarter. Finally, Bangor Savings Bank increased its holdings in shares of Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Down 0.7%

Shares of Boston Scientific stock opened at $46.83 on Friday. The company has a market capitalization of $69.60 billion, a PE ratio of 19.59, a P/E/G ratio of 0.89 and a beta of 0.56. Boston Scientific Corporation has a 1-year low of $45.99 and a 1-year high of $109.50. The business has a 50-day moving average of $56.37 and a 200-day moving average of $74.95. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same period last year, the firm earned $0.75 earnings per share. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a stock buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s management believes its shares are undervalued.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Bank of America dropped their price objective on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Royal Bank Of Canada reissued an “outperform” rating on shares of Boston Scientific in a research note on Thursday, May 28th. Stifel Nicolaus set a $75.00 price target on Boston Scientific in a report on Wednesday, May 27th. BTIG Research reduced their price objective on Boston Scientific from $80.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, June 2nd. Finally, Weiss Ratings cut Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $85.08.

Insiders Place Their Bets

In other news, Director Edward J. Ludwig acquired 3,580 shares of the stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the transaction, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David C. Habiger purchased 2,250 shares of the stock in a transaction dated Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the acquisition, the director owned 13,878 shares in the company, valued at $776,057.76. This represents a 19.35% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have bought 9,800 shares of company stock worth $554,012. Corporate insiders own 0.34% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts remain constructive on Boston Scientific, with one note saying the stock could still rise sharply from current levels despite this year’s de-rating. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Positive Sentiment: Boston Scientific may benefit from Penumbra’s newly FDA-cleared stroke thrombectomy platform, which one analyst said could add about $100 million in incremental revenue over time. Penumbra’s FDA nod for clot removal tech a win for Boston Scientific
• Positive Sentiment: BTIG stayed bullish on BSX, pointing to valuation and substantial upside potential despite the recent decline in the share price. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
• Positive Sentiment: Boston Scientific reported strong catheter study results, which could support confidence in its clinical pipeline and product adoption. Boston Scientific Corp (BSX) Reports Strong Success Rates From Catheter Study
• Neutral Sentiment: Erste Group trimmed its FY2026 and FY2027 EPS estimates slightly, a modest negative on expectations but not a major change to the broader consensus. Boston Scientific Corporation (NYSE:BSX) – Free Report
• Negative Sentiment: Boston Scientific has repeatedly walked back full-year 2026 guidance, and that ongoing uncertainty is pressuring the stock and contributing to its decline. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Negative Sentiment: One Seeking Alpha piece argues the market is treating BSX like a “broken compounder,” reflecting skepticism that has weighed on the shares. Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.